arbemnifosbuvir

Arbemnifosbuvir (AT-752) is a novel, orally administered small molecule antiviral developed for the treatment and prophylaxis of dengue virus infection. It is a double prodrug of a guanosine nucleotide analog that is metabolized in vivo to its active triphosphate form, AT-9010. The drug acts by inhibiting the dengue virus NS5 enzyme through two mechanisms: it targets both the RNA-dependent RNA polymerase (RdRp) at its RNA elongation step and the RNA 2'-O-methyltransferase (MTase), leading to inhibition of viral replication via chain termination and prevention of proper viral mRNA capping. Preclinical studies have shown potent activity against all four dengue serotypes as well as other flaviviruses. Clinical trials have demonstrated favorable safety and pharmacokinetic profiles in healthy volunteers. Arbemnifosbuvir has received Fast Track designation from the US FDA for dengue treatment[1][2][3][4][5][6].

Other names

arbemnifosbuvir